Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Completed
Conditions studied: Leukemia, Chronic Myeloid
In brief
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line therapy.
Key facts
- Study ID
- NCT07188428
- Run by
- Novartis Pharmaceuticals
- People needed
- 2298
- Starts
- 2024-02-27
- Expected to finish
- 2024-12-02
- Last updated by the study team
- 2025-09-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- L Cohort:
- Patients had at least one diagnosis for CML (International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM]: C92.1x) during the observation period.
- Patients ≥18 years of age as of the first CML diagnosis.
- Patients received imatinib, dasatinib, nilotinib, or bosutinib in 1L.
- Patients initiated 1L within a maximum of 3 months following the first observed CML diagnosis.
- Patients had at least 12 months of continuous enrollment prior to the index date.
- Patients had at least 6 months of continuous enrollment post index date (including index date).
- L Cohort:
- Patients in the 1L cohort.
- Patients received imatinib, dasatinib, nilotinib, bosutinib, ponatinib or asciminib in 2L.
- Patients with at least 12 months of continuous enrollment prior to the index date.
- Patients with at least 6 months of continuous enrollment post index date (including index date).
You may not qualify if…
- L Cohort:
- Patients with medical services with a procedure code for imatinib any time during the observation period.
- Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time in the baseline period before the 1L initiation.
- Patients with a medical claim associated with a clinical trial drug during the baseline period before the 1L initiation up to the end of the observation period.
- Patients who received chemotherapy, or a TKI of interest or had a hematopoietic stem cell transplantation (HSCT) during the baseline period before 1L initiation.
- L Cohort:
- Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time before the 2L initiation.
Where it is running
- Novartis — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.